Immunoglobulin A (IgA) Nephropathy - Competitive Landscape, Epidemiology Forecast, and Pipeline Analysis, 2018

Chapter 1. Research Background

1.1 Research Objectives

1.2 Definition

1.3 Research Scope

1.3.1 Pipeline Analysis by Phase

1.3.2 Pipeline Analysis by Molecule Type

1.3.3 Pipeline Analysis by Route of Administration

1.4 Key Stakeholders

Chapter 2. Research Methodology

2.1 Secondary Research

2.1.1 Secondary Sources for Epidemiology Analysis

2.2 Primary Research

2.2.1 Breakdown of Primary Research Respondents

2.2.1.1 By industry participant

2.2.1.2 By company type

2.2.2 KOLs Validation

2.3 Coverage of Epidemiology Analysis

2.4 Forecast Methodology for Epidemiology Analysis

2.5 Assumptions for Epidemiology Analysis

Chapter 3. Executive Summary

Chapter 4. Pipeline Outlook

4.1 Disease Overview

4.2 Causes

4.3 Signs and Symptoms

4.4 Pathophysiology

4.5 Diagnosis

4.6 Treatment

4.7 Key Drivers

4.7.1 Lack of Availability of Specific Treatment

4.7.2 Development of Various Promising Targets

4.8 Key Barrier

4.8.1 No Early Signs or Symptoms

4.9 IgA Nephropathy Therapeutics Pipeline Analysis

4.9.1 Pipeline Analysis by Phase

4.9.2 Pipeline Analysis by Molecule Type

4.9.3 Pipeline Analysis by Route of Administration

4.9.4 Pipeline Analysis by Company

Chapter 5. IgA Nephropathy Epidemiology Overview

5.1 IgA Nephropathy Epidemiology Forecast for 7MM

5.1.1 IgA Nephropathy Epidemiology Forecast for the U.S.

5.1.2 IgA Nephropathy Epidemiology Forecast for Japan

5.1.3 IgA Nephropathy Epidemiology Forecast for EU5

5.1.3.1 IgA nephropathy epidemiology for the U.K.

5.1.3.2 IgA nephropathy epidemiology for Germany

5.1.3.3 IgA nephropathy epidemiology for France

5.1.3.4 IgA nephropathy epidemiology for Italy

5.1.3.5 IgA nephropathy epidemiology for Spain

Chapter 6. IgA Nephropathy Conferences (2018)

6.1 Recently Organized/Held Seminars and Conferences

6.2 Upcoming Seminar and Conferences

Chapter 7. IgA Nephropathy Therapeutics Pipeline Analysis by Phase (2018) 60

7.1 Phase III

7.1.1 ACTH (Acthar) Gel

7.1.1.1 Clinical trials

7.1.1.2 Clinical results

7.1.1.3 Strategic development

7.1.2 XXXX

7.1.2.1 Clinical trials

7.1.2.2 Clinical results

7.1.2.3 Strategic development

7.1.2.4 Designation

7.1.2.5 Patent

7.1.2.6 Financing

7.1.2.7 Technology

7.1.3 XXXX

7.1.3.1 Clinical trials

7.1.3.2 Clinical results

7.1.3.3 Strategic development

7.1.3.4 Designation

7.1.4 XXXX

7.1.4.1 Clinical trials

7.1.4.2 Strategic development

7.2 Phase II/III

7.2.1 Blisibimod

7.2.1.1 Clinical trials

7.2.1.2 Clinical results

7.2.1.3 Strategic development

7.3 Phase II

7.3.1 Atacicept

7.3.1.1 Clinical trials

7.3.2 XXXX

7.3.2.1 Clinical trials

7.3.2.2 Clinical results

7.3.3 XXXX

7.3.3.1 Clinical trials

7.3.4 XXXX

7.3.4.1 Clinical trials

7.3.5 XXXX

7.3.5.1 Clinical trials

7.3.6 XXXX

7.3.6.1 Clinical trials

7.3.6.2 Clinical trial results

7.3.6.3 Strategic development

7.4 Phase I

7.4.1 VIS649

7.4.1.1 Pre-Clinical study

7.4.1.2 Clinical trials

7.4.1.3 Strategic development

7.4.1.4 Technology

7.5 Pre-Clinical

7.5.1 IgA Protease

7.5.1.1 Grant

7.5.2 XXXX

7.5.3 XXXX

7.6 Unknown

7.6.1 IL-6 antibody

7.6.1.1 Patent

7.6.2 XXXX

7.7 Discovery

7.7.1 Drug Candidate for IgA Nephropathy - Polyneuron Pharmaceuticals AG

7.8 Inactive

7.8.1 Ramipril

7.8.1.1 Clinical trials

7.8.1.2 Strategic development

7.8.2 XXXX

7.8.2.1 Clinical trials

7.8.3 XXXX

7.8.3.1 Clinical trials

7.8.4 XXXX

7.8.4.1 Clinical trials

7.9 Discontinued

7.9.1 SM101

7.9.1.1 Clinical trials

7.9.2 XXXX

Chapter 8. Clinical Trials Review

8.1 Clinical Trials by Region

8.2 Clinical Trials by Trial Status

Chapter 9. Competitive Landscape

9.1 Key Player Benchmarking

9.2 SWOT Analysis of IgA Nephropathy Pipeline

Chapter 10. Company Profiles

10.1 Mallinckrodt plc

10.1.1 Business Overview

10.1.2 Product Offerings

10.2 Visterra Inc.

10.2.1 Business Overview

10.2.2 Product Offerings

10.3 XXXX.

10.3.1 Business Overview

10.3.2 Product Offerings

10.4 XXXX

10.4.1 Business Overview

10.4.2 Product Offerings

10.5 XXXX

10.5.1 Business Overview

10.5.2 Product Offerings

10.6 Omeros Corporation

10.6.1 Business Overview

10.6.2 Product Offerings

10.7 XXXX

10.7.1 Business Overview

10.7.2 Product Offerings

10.8 IGAN Biosciences Inc.

10.8.1 Business Overview

10.8.2 Product Offerings

Chapter 11. Appendix

11.1 Abbreviation

11.2 Related Reports

 

LIST OF TABLES

 

TABLE 1 PIPELINE ANALYSIS OF IGA NEPHROPATHY THERAPEUTICS, BY COMPANY (2018)

TABLE 2 IGA NEPHROPATHY EPIDEMIOLOGY FOR 7MM (2016-2021)

TABLE 3 IGA NEPHROPATHY EPIDEMIOLOGY FOR 7MM (2022-2028)

TABLE 4 IGA NEPHROPATHY EPIDEMIOLOGY FOR THE U.S. (2016-2021)

TABLE 5 IGA NEPHROPATHY EPIDEMIOLOGY FOR THE U.S. (2022-2028)

TABLE 6 IGA NEPHROPATHY EPIDEMIOLOGY FOR JAPAN (2016-2021)

TABLE 7 IGA NEPHROPATHY EPIDEMIOLOGY FOR JAPAN (2022-2028)

TABLE 8 IGA NEPHROPATHY EPIDEMIOLOGY FOR EU5 (2016-2021)

TABLE 9 IGA NEPHROPATHY EPIDEMIOLOGY FOR EU5 (2022-2028)

TABLE 10 IGA NEPHROPATHY EPIDEMIOLOGY FOR THE U.K. (2016-2021)

TABLE 11 IGA NEPHROPATHY EPIDEMIOLOGY FOR THE U.K. (2022-2028)

TABLE 12 IGA NEPHROPATHY EPIDEMIOLOGY FOR GERMANY (2016-2021)

TABLE 13 IGA NEPHROPATHY EPIDEMIOLOGY FOR GERMANY (2022-2028)

TABLE 14 IGA NEPHROPATHY EPIDEMIOLOGY FOR FRANCE (2016-2021)

TABLE 15 IGA NEPHROPATHY EPIDEMIOLOGY FOR FRANCE (2022-2028)

TABLE 16 IGA NEPHROPATHY EPIDEMIOLOGY FOR ITALY (2016-2021)

TABLE 17 IGA NEPHROPATHY EPIDEMIOLOGY FOR ITALY (2022-2028)

TABLE 18 IGA NEPHROPATHY EPIDEMIOLOGY FOR SPAIN (2016-2021)

TABLE 19 IGA NEPHROPATHY EPIDEMIOLOGY FOR SPAIN (2022-2028)

TABLE 20 KEY IGA NEPHROPATHY CONFERENCES HELD IN 2018

TABLE 21 UPCOMING IGA NEPHROPATHY SEMINAR AND CONFERENCES

TABLE 22 DESCRIPTION OF ACTH (ACTHAR) GEL

TABLE 23 CLINICAL TRIALS OF ACTH (ACTHAR) GEL

TABLE 24 DESCRIPTION OF NEFECON

TABLE 25 CLINICAL TRIALS OF NEFECON

TABLE 26 DESCRIPTION OF XXXX

TABLE 27 CLINICAL TRIALS OF XXXX

TABLE 28 DESCRIPTION OF XXXX

TABLE 29 CLINICAL TRIALS OF XXXX

TABLE 30 DESCRIPTION OF BLISIBIMOD

TABLE 31 CLINICAL TRIALS OF BLISIBIMOD

TABLE 32 DESCRIPTION OF ATACICEPT

TABLE 33 CLINICAL TRIALS OF ATACICEPT

TABLE 34 DESCRIPTION OF XXXX

TABLE 35 CLINICAL TRIALS OF XXXX

TABLE 36 CLINICAL TRIALS PHASE II RESULTS OF XXXX

TABLE 37 DESCRIPTION OF XXXX

TABLE 38 CLINICAL TRIALS OF XXXX

TABLE 39 DESCRIPTION OF XXXX

TABLE 40 DESCRIPTION OF XXXX

TABLE 41 CLINICAL TRIALS OF XXXX

TABLE 42 DESCRIPTION OF XXXX

TABLE 43 CLINICAL TRIALS OF XXXX

TABLE 44 DESCRIPTION OF VIS649

TABLE 45 CLINICAL TRIALS OF VIS649

TABLE 46 DESCRIPTION OF IGA PROTEASE

TABLE 47 DESCRIPTION OF XXXX

TABLE 48 DESCRIPTION OF XXXX

TABLE 49 DESCRIPTION OF IL-6 ANTIBODY

TABLE 50 DESCRIPTION OF XXXX

TABLE 51 DESCRIPTION OF DRUG CANDIDATE FOR IGA NEPHROPATHY - POLYNEURON PHARMACEUTICALS AG

TABLE 52 DESCRIPTION OF RAMIPRIL

TABLE 53 CLINICAL TRIALS OF RAMIPRIL

TABLE 54 DESCRIPTION OF XXXX

TABLE 55 CLINICAL TRIALS OF XXXX

TABLE 56 DESCRIPTION OF XXXX

TABLE 57 CLINICAL TRIALS OF XXXX

TABLE 58 DESCRIPTION OF XXXX

TABLE 59 CLINICAL TRIALS OF XXXX

TABLE 60 DESCRIPTION OF SM101

TABLE 61 CLINICAL TRIALS OF SM101

TABLE 62 DESCRIPTION OF XXXX

TABLE 63 CLINICAL TRIALS OF XXXX

TABLE 64 MALLINCKRODT PLC – AT A GLANCE

TABLE 65 XXXX – AT A GLANCE

TABLE 66 XXXX – AT A GLANCE

TABLE 67 XXXX – AT A GLANCE

TABLE 68 XXXX – AT A GLANCE

TABLE 69 OMEROS CORPORATION – AT A GLANCE

TABLE 70 XXXX – AT A GLANCE

TABLE 71 XXXX. – AT A GLANCE

 

LIST OF FIGURES

 

FIG 1 RESEARCH METHODOLOGY

FIG 2 BREAKDOWN OF PRIMARY RESEARCH RESPONDENTS, BY INDUSTRY PARTICIPANT

FIG 3 BREAKDOWN OF PRIMARY RESEARCH RESPONDENTS, BY COMPANY TYPE

FIG 4 PATHOPHYSIOLOGY OF IGA NEPHROPATHY

FIG 5 TREATMENT ALGORITHM OF IGA NEPHROPATHY

FIG 6 IGA NEPHROPATHY DRUG CANDIDATES UNDER DEVELOPMENT (2018)

FIG 7 IGA NEPHROPATHY PIPELINE SPLIT, BY MOLECULE TYPE (2018)

FIG 8 IGA NEPHROPATHY PIPELINE SPLIT, BY ROUTE OF ADMINISTRATION (2018)

FIG 9 TOTAL NUMBER OF PREVALENT CASES FOR 7MM (2016 & 2028)

FIG 10 IGA NEPHROPATHY PREVALENCE RATE IN 7MM (2016-2028)

FIG 11 IGA NEPHROPATHY EPIDEMIOLOGY FOR 7MM (2016-2028)

FIG 12 IGA NEPHROPATHY EPIDEMIOLOGY FOR THE U.S. (2016-2028)

FIG 13 IGA NEPHROPATHY EPIDEMIOLOGY FOR JAPAN (2016-2028)

FIG 14 IGA NEPHROPATHY EPIDEMIOLOGY FOR EU5 (2016-2028)

FIG 15 IGA NEPHROPATHY EPIDEMIOLOGY FOR THE U.K. (2016-2028)

FIG 16 IGA NEPHROPATHY EPIDEMIOLOGY FOR GERMANY (2016-2028)

FIG 17 IGA NEPHROPATHY EPIDEMIOLOGY FOR FRANCE (2016-2028)

FIG 18 IGA NEPHROPATHY EPIDEMIOLOGY FOR ITALY (2016-2028)

FIG 19 IGA NEPHROPATHY EPIDEMIOLOGY FOR SPAIN (2016-2028)

FIG 20 PHASE II RESULTS OF OMS721 IN IGA NEPHROPATHY: 24-HR URINE PROTEIN (1)

FIG 21 PHASE II RESULTS OF OMS721 IN IGA NEPHROPATHY: 24-HR URINE PROTEIN (2)

FIG 22 PHASE II AND FOLLOW-UP RESULTS – IGA NEPHROPATHY: EGFR

FIG 23 BREAKDOWN OF CLINICAL TRIALS, BY REGION

FIG 24 BREAKDOWN OF CLINICAL TRIALS, BY TRIAL STATUS

FIG 25 KEY PLAYER BENCHMARKING

FIG 26 SWOT ANALYSIS OF IGA NEPHROPATHY PIPELINE